Cullinan Therapeutics's current cash is $75M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2026), CGEM shows a current cash of $75M. That compares with $77M in the prior-year period — down 2.1% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, CGEM's current cash is now $75M (was $77M) — a 2.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Cullinan Therapeutics is outperforming or lagging.
Tracking CGEM's current cash over time shows whether Cullinan Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $75M That compares with $77M in the prior-year period — down 2.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this current cash page, Stockcircle has Cullinan Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $75M) with ownership activity and broader fundamentals.
Cullinan Therapeutics's current cash is $75M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.